HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings In Brief

This article was originally published in The Rose Sheet

Executive Summary

Church & Dwight: Firm's eight "power brands" including Arm & Hammer, Orajel, First Response, SpinBrush and Nair are growing in 2008, C&D Chairman & CEO Jim Craigie says during Nov. 4 earnings call. Accounting for 80% of net revenue and profit, those eight franchises are being supported with new product launches and advertising and are projected to deliver firm's 3% to 4% organic revenue growth target. U.S. sales in the third quarter totaled $444.7 mil., up 9.7%. Arm & Hammer Dental Care toothpaste contributed to growth, firm says. International sales were $112.6 mil., a 4.3% increase. Firm completed its acquisition of Del Pharmaceuticals in the quarter, after having announced the $380 mil. purchase from Coty in April (1"The Rose Sheet" April 7, 2008, p. 7). Church & Dwight discussed its strategy for riding out a shaky market in its Q2 earnings call (2"The Rose Sheet" Aug. 11, 2008, p. 9)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel